AAAAAA

   
Results: 1-12 |
Results: 12
T-cell mean telomere lengths changes in treatment naive HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
Authors: Aladdin, H Von Essen, M Schjerling, P Katzenstein, T Gerstoft, J Skinhoj, P Pedersen, BK Ullum, H
Citation: H. Aladdin et al., T-cell mean telomere lengths changes in treatment naive HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART, SC J IMMUN, 54(3), 2001, pp. 301-305
Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients
Authors: Aladdin, H Larsen, CS Schjerling, P Moller, BK Buhl, MR Gerstoft, J Pedersen, BK Ullum, H
Citation: H. Aladdin et al., Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients, SC J IMMUN, 53(3), 2001, pp. 315-319
The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
Authors: Nielsen, SD Sorensen, TU Aladdin, H Ersboll, AK Mathiesen, L Ullum, H Gerstoft, J Nielsen, JO Pedersen, BK Nielsen, SD
Citation: Sd. Nielsen et al., The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals, SC J IMMUN, 52(3), 2000, pp. 298-303
Effects of G-CSF on telomere lengths in PBMCs from human immunodeficiency virus-infected patients: Results from a randomized, placebo-controlled trial
Authors: Aladdin, H Ullum, H Schjerling, P Jensen, MS Nielsen, SD Mathiesen, L Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Effects of G-CSF on telomere lengths in PBMCs from human immunodeficiency virus-infected patients: Results from a randomized, placebo-controlled trial, SC J IMMUN, 52(2), 2000, pp. 212-216
Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
Authors: Aladdin, H Ullum, H Katzenstein, T Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART, SC J IMMUN, 51(5), 2000, pp. 520-525
Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients
Authors: Aladdin, H Larsen, CS Moller, BK Ullum, H Buhl, MR Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients, SC J IMMUN, 51(2), 2000, pp. 168-175
Granulocyte colony-stimulating factor increases CD4(+) T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial
Authors: Aladdin, H Ullum, H Nielsen, SD Espersen, C Mathiesen, L Katzenstein, TL Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Granulocyte colony-stimulating factor increases CD4(+) T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial, J INFEC DIS, 181(3), 2000, pp. 1148-1152
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis
Authors: Katzenstein, TL Dickmeiss, E Aladdin, H Hede, A Nielsen, C Nielsen, H Jorgensen, LB Gerstoft, J
Citation: Tl. Katzenstein et al., Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis, ANN INT MED, 133(1), 2000, pp. 31-34
Immune function and phenotype before and after highly active antiretroviral therapy
Authors: Sondergaard, SR Aladdin, H Ullum, H Gerstoft, J Skinhoj, P Pedersen, BK
Citation: Sr. Sondergaard et al., Immune function and phenotype before and after highly active antiretroviral therapy, J ACQ IMM D, 21(5), 1999, pp. 376-383
Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death
Authors: Aladdin, H Ullum, H Lepri, AC Leffers, H Katzenstein, T Gerstoft, J Gjedde, SB Phillips, AN Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Bulk culture levels of specific cytotoxic T-cell activity against HIV-1 proteins are not associated with risk of death, SC J IMMUN, 50(2), 1999, pp. 223-227
Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment
Authors: Ullum, H Katzenstein, T Aladdin, H Nielsen, C Sondergaard, SR Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Ullum et al., Immunological changes in human immunodeficiency virus (HIV)-infected individuals during HIV-specific protease inhibitor treatment, SC J IMMUN, 49(5), 1999, pp. 539-547
Natural immunity and HIV disease progression
Authors: Ullum, H Lepri, AC Aladdin, H Katzenstein, T Victor, J Phillips, AN Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Ullum et al., Natural immunity and HIV disease progression, AIDS, 13(5), 1999, pp. 557-563
Risultati: 1-12 |